Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
Bone Biologics (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, has appointed Phillip T. Meikle to its Board of Directors. Mr. Meikle brings over 30 years of commercial experience in the orthopedic and spine industry. He succeeds Don R. Hankey, who retired after seven years of service. The board remains at four directors.
Mr. Meikle was previously the president and CEO of Biosystems of New England, Inc., an orthopedic distribution company he founded in 1992 and sold to Stryker in 2019. He has been a consultant to Stryker Spine for the past five years. His company served as a distributor for Stryker Spine from 2002 to 2019 and for Medtronic Spine from 1992 to 2002.
Jeffrey Frelick, president and CEO of Bone Biologics, expressed enthusiasm about Mr. Meikle's appointment, citing his extensive experience with orthopedic and spine products as particularly valuable as the company develops NB1 for spinal fusion patients.
Bone Biologics (Nasdaq: BBLG, BBLGW), sviluppatore di prodotti ortobiologici per il mercato della fusione spinale, ha nominato Phillip T. Meikle nel suo Consiglio di Amministrazione. Il Sig. Meikle porta con sé oltre 30 anni di esperienza commerciale nell'industria ortopedica e spinale. Sostituisce Don R. Hankey, che si è ritirato dopo sette anni di servizio. Il consiglio rimane composto da quattro membri.
Il Sig. Meikle è stato precedentemente il presidente e CEO di Biosystems of New England, Inc., una compagnia di distribuzione ortopedica che ha fondato nel 1992 e venduto a Stryker nel 2019. Negli ultimi cinque anni è stato consulente per Stryker Spine. La sua azienda ha servito come distributore per Stryker Spine dal 2002 al 2019 e per Medtronic Spine dal 1992 al 2002.
Jeffrey Frelick, presidente e CEO di Bone Biologics, ha espresso entusiasmo riguardo alla nomina del Sig. Meikle, citando la sua vasta esperienza con prodotti ortopedici e spinali come particolarmente preziosa mentre l'azienda sviluppa NB1 per pazienti sottoposti a fusione spinale.
Bone Biologics (Nasdaq: BBLG, BBLGW), desarrollador de productos ortobiológicos para el mercado de fusión espinal, ha nombrado a Phillip T. Meikle en su Junta Directiva. El Sr. Meikle cuenta con más de 30 años de experiencia comercial en la industria ortopédica y espinal. Sucede a Don R. Hankey, quien se retiró tras siete años de servicio. La junta se compone de cuatro directores.
El Sr. Meikle fue anteriormente presidente y CEO de Biosystems of New England, Inc., una compañía de distribución ortopédica que fundó en 1992 y vendió a Stryker en 2019. Ha sido consultor para Stryker Spine durante los últimos cinco años. Su empresa sirvió como distribuidor para Stryker Spine desde 2002 hasta 2019 y para Medtronic Spine desde 1992 hasta 2002.
Jeffrey Frelick, presidente y CEO de Bone Biologics, expresó entusiasmo por el nombramiento del Sr. Meikle, citando su amplia experiencia con productos ortopédicos y espinales como particularmente valiosa mientras la empresa desarrolla NB1 para pacientes de fusión espinal.
Bone Biologics (Nasdaq: BBLG, BBLGW)는 척추 융합 시장을 위한 정형외과 생물학 제품을 개발하는 회사로서 Phillip T. Meikle을 이사회의 일원으로 임명했습니다. Meikle은 정형외과 및 척추 산업에서 30년 이상의 상업적 경험을 보유하고 있습니다. 그는 7년 동안 봉사한 Don R. Hankey의 후임입니다. 이사회는 총 4명의 이사로 구성되어 있습니다.
Meikle은 1992년에 설립하고 2019년에 Stryker에 매각한 정형외과 유통 회사인 Biosystems of New England, Inc.의 전 회장 겸 CEO였습니다. 그는 지난 5년 동안 Stryker Spine의 자문을 맡아왔습니다. 그의 회사는 2002년부터 2019년까지 Stryker Spine의 유통업체로, 1992년부터 2002년까지는 Medtronic Spine의 유통업체로 활동했습니다.
Jeffrey Frelick, Bone Biologics의 회장 겸 CEO는 Meikle의 임명에 대해 기쁨을 표하며, 특히 회사를 위해 척추 융합 환자를 위한 NB1을 개발하는 동안 그가 가진 정형외과 및 척추 제품에 대한 폭넓은 경험이 매우 가치 있다고 언급했습니다.
Bone Biologics (Nasdaq: BBLG, BBLGW), un développeur de produits ortobiologiques pour le marché de la fusion vertébrale, a nommé Phillip T. Meikle à son Conseil d'Administration. M. Meikle apporte plus de 30 ans d'expérience commerciale dans l'industrie orthopédique et vertébrale. Il succède à Don R. Hankey, qui a pris sa retraite après sept ans de service. Le conseil reste composé de quatre membres.
M. Meikle était auparavant président et PDG de Biosystems of New England, Inc., une société de distribution orthopédique qu'il a fondée en 1992 et vendue à Stryker en 2019. Il a été consultant pour Stryker Spine au cours des cinq dernières années. Sa société a été distributeur pour Stryker Spine de 2002 à 2019 et pour Medtronic Spine de 1992 à 2002.
Jeffrey Frelick, président et PDG de Bone Biologics, a exprimé son enthousiasme concernant la nomination de M. Meikle, en soulignant que son expérience approfondie avec les produits orthopédiques et vertébraux est particulièrement précieuse alors que l'entreprise développe le NB1 pour les patients subissant une fusion vertébrale.
Bone Biologics (Nasdaq: BBLG, BBLGW), ein Entwickler von orthobiologischen Produkten für den Markt der Wirbelsäulenfusion, hat Phillip T. Meikle in seinen Vorstand berufen. Herr Meikle bringt über 30 Jahre kommerzielle Erfahrung in der orthopädischen und Wirbelsäulenindustrie mit. Er folgt Don R. Hankey nach, der nach sieben Jahren im Dienste retire. Der Vorstand besteht aus vier Direktoren.
Herr Meikle war zuvor Präsident und CEO von Biosystems of New England, Inc., einem von ihm im Jahr 1992 gegründeten und 2019 an Stryker verkauften orthopädischen Vertriebsunternehmen. In den letzten fünf Jahren war er Berater für Stryker Spine. Sein Unternehmen war von 2002 bis 2019 Distributor für Stryker Spine und von 1992 bis 2002 für Medtronic Spine.
Jeffrey Frelick, Präsident und CEO von Bone Biologics, äußerte sich begeistert über die Ernennung von Herrn Meikle und nannte seine umfangreiche Erfahrung mit orthopädischen und Wirbelsäulenprodukten als besonders wertvoll, während das Unternehmen NB1 für Patienten mit Wirbelsäulenfusion entwickelt.
- Appointment of Phillip T. Meikle, bringing 30+ years of orthopedic and spine industry experience to the board
- Meikle's extensive industry relationships and knowledge could benefit the company's product development and distribution strategies
- Timely addition as the company works on developing NB1 for spinal fusion patients
- None.
Brings 30+ years of commercial experience in the orthopedic and spine industry
Mr. Meikle most recently was president and chief executive officer of Biosystems of New England, Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He has broad experience representing diverse and innovative orthopedic and spine industry companies in developing and distributing innovative products. Mr. Meikle has been a consultant to Stryker Spine for the past five years.
Biosystems of New England served as a distributor for Stryker Spine from 2002 to 2019, and for Medtronic Spine from 1992 to 2002.
“The appointment of Phillip Meikle to our board of directors is particularly timely as we work to develop NB1 for spinal fusion patients. He brings a wealth of experience with orthopedic and spine products, and we look forward to benefitting from his knowledge, experience and industry relationships. We are delighted that a professional of Phil’s stature has agreed to join our board,” said Jeffrey Frelick, president and chief executive officer of Bone Biologics. “On behalf of Bone Biologics and our board of directors, I extend heartfelt thanks to Don Hankey for his service as Chairman and his long-standing support of our company, without which we would not be where we are today.”
Mr. Meikle holds a B.S. from
About Bone Biologics
Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking work with select strategic partners that builds on the preclinical research of the NELL-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. For more information, please visit www.bonebiologics.com.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements regarding the expected results and performance of Mr. Meikle and the ability of the company to develop the Company’s lead product candidate NB1 for spinal fusion patients, as well as statements containing the words “look forward” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those contained in its forward-looking statements as a result of a number of factors, including, but not limited to, market and other conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241021983057/en/
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
Source: Bone Biologics
FAQ
Who is the new board member appointed by Bone Biologics (BBLG)?
What is Phillip T. Meikle's background in relation to Bone Biologics (BBLG)?
How does Phillip T. Meikle's appointment align with Bone Biologics' (BBLG) current focus?
Who did Phillip T. Meikle replace on the Bone Biologics (BBLG) board?
